Cost-effectiveness analysis, welfare economics, and the societal perspective: a reply

被引:0
|
作者
Bengt Liljas
机构
[1] AstraZeneca,Department of Economics
[2] Lund University,undefined
关键词
Cost-effectiveness analysis; QALYs; Welfare economics; Societal perspective; D61; D81; I10;
D O I
暂无
中图分类号
学科分类号
摘要
A critical question in cost-effectiveness analysis (CEA) is what costs should be included. In an earlier paper in this journal, I argued that the same principle (internal consistency) that has been applied to the discussion about future non-medical costs should also be applied to the case when survival is not affected. Internal consistency in this case implies that a cost should only be included if its corresponding utility is also included. As Quality-Adjusted Life-Years can rarely be considered to be consistent with a broad definition of utility, I built a case for recommending to not including the costs for changes in consumption and absence from work (whereas changes in the productivity at work may still be included) when applying a welfare theoretic foundation. As one of several parts of building this case, and to further highlight the elements of importance, I constructed a simple welfare theoretic model. Unfortunately, this model did not take the envelope theorem into account (which was correctly pointed out by Prof. Friedrich Breyer). However, most of the arguments still hold and the policy implications are actually even confirmed in the analysis by Prof. Friedrich Breyer. Building on these results, a related and equally interesting question is what the implications are on the so-called societal perspective. It seems as if a societal perspective in CEA may not be consistent with a welfare theoretic foundation. However, even if such a foundation is not seen as important, it may still be of interest—for reasons of internal consistency—to take a societal perspective on both costs and benefits.
引用
收藏
页码:597 / 598
页数:1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis - a health policy perspective
    Maini, BS
    SURGERY, 1999, 126 (05) : 989 - 989
  • [32] Costing and Perspective in Published Cost-Effectiveness Analysis
    Neumann, Peter J.
    MEDICAL CARE, 2009, 47 (07) : S28 - S32
  • [33] Societal Perspectives and Real-World Cost-Effectiveness: Expanding the Scope of Health Economics Inquiry
    Longo, Christopher J. J.
    CURRENT ONCOLOGY, 2023, 30 (01) : 233 - 235
  • [34] COST-EFFECTIVENESS AND HUMAN-WELFARE
    OLDENBURG, TR
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 1980, 100 (01): : 10 - 10
  • [35] THE COST-EFFECTIVENESS OF TRASTUZUMAB OVER THE PRODUCT LIFE CYCLE IN PORTUGAL: A DYNAMIC AND SOCIETAL PERSPECTIVE
    Garrison, L.
    Babigumira, J. B.
    Andrade, S.
    VALUE IN HEALTH, 2012, 15 (07) : A425 - A425
  • [36] COST-EFFECTIVENESS OF GLYCOPYRRONIUM COMPARED TO TIOTROPIUM IN COPD PATIENTS FROM A SWEDISH SOCIETAL PERSPECTIVE
    Costa-Scharplatz, M.
    Tambour, M.
    Henriksson, F.
    Stallberg, B.
    VALUE IN HEALTH, 2013, 16 (07) : A371 - A372
  • [37] Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective
    Hornberger, John
    Michalopoulos, Steven
    Dai, Minghan
    Andrade, Paula
    Dilla, Tatiana
    Happich, Michael
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2015, 18 (02): : 63 - 73
  • [38] COST-EFFECTIVENESS METHODOLOGY - REPLY
    GAGNON, JP
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1988, 22 (05): : 429 - 430
  • [39] CLOZAPINES COST-EFFECTIVENESS - REPLY
    MELTZER, HY
    COLA, P
    AMERICAN JOURNAL OF PSYCHIATRY, 1995, 152 (01): : 153 - 154
  • [40] Cost-Effectiveness: The Authors Reply
    Pauly, Mark V.
    Sloan, Frank A.
    Sullivan, Sean D.
    HEALTH AFFAIRS, 2015, 34 (01)